Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.36)
# 3,382
Out of 4,761 analysts
112
Total ratings
36.84%
Success rate
-12.22%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $298 → $265 | $137.08 | +93.32% | 20 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $7.15 | +11.89% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $9.33 | +682.42% | 7 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $163 | $116.11 | +40.38% | 14 | Feb 7, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Hold | $119 → $132 | $128.54 | +2.69% | 5 | Jan 31, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $2.30 | +3,378.26% | 7 | Jan 6, 2025 | |
| CRVO CervoMed | Maintains: Buy | $65 → $12 | $2.33 | +416.13% | 4 | Dec 11, 2024 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $14.00 | +100.00% | 4 | Nov 18, 2024 | |
| ATAI Atai Life Sciences | Maintains: Buy | $11 | $2.04 | +439.22% | 1 | Nov 18, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $23 | $7.83 | +193.74% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 | $4.26 | +228.64% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $4.51 | +1,740.35% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $8.18 | +71.15% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $48 | $4.54 | +957.27% | 2 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $12 | $5.12 | +134.38% | 4 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $8.74 | +128.83% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $2.23 | +1,065.92% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $20.29 | +62.64% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $39.77 | +277.17% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.00 | - | 2 | Jan 31, 2017 |
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $298 → $265
Current: $137.08
Upside: +93.32%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $7.15
Upside: +11.89%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $9.33
Upside: +682.42%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $172 → $163
Current: $116.11
Upside: +40.38%
Intra-Cellular Therapies
Jan 31, 2025
Downgrades: Hold
Price Target: $119 → $132
Current: $128.54
Upside: +2.69%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.30
Upside: +3,378.26%
CervoMed
Dec 11, 2024
Maintains: Buy
Price Target: $65 → $12
Current: $2.33
Upside: +416.13%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.00
Upside: +100.00%
Atai Life Sciences
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $2.04
Upside: +439.22%
Zevra Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $7.83
Upside: +193.74%
Nov 14, 2024
Maintains: Buy
Price Target: $14
Current: $4.26
Upside: +228.64%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.51
Upside: +1,740.35%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $8.18
Upside: +71.15%
Aug 2, 2024
Maintains: Buy
Price Target: $50 → $48
Current: $4.54
Upside: +957.27%
Jun 13, 2024
Downgrades: Hold
Price Target: $120 → $12
Current: $5.12
Upside: +134.38%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $8.74
Upside: +128.83%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $2.23
Upside: +1,065.92%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $20.29
Upside: +62.64%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $39.77
Upside: +277.17%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.00
Upside: -